EMA agrees on "black triangle" for new drugs launched in EU
This article was originally published in SRA
Executive Summary
All new products launched in the EU will have to display a black inverted triangle on their product information to denote that the product is subject to additional monitoring if the European Commission accepts the advice of the European Medicines Agency’s new pharmacovigilance committee, the PRAC1.